K-Ras wild-type
1 drugsPredictive biomarker for patient selection in 4 indications
1
Approved Drugs
4
Indications
1
Companies
K-Ras wild-type is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 4 indications including Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck, Colorectal Cancer. Explore the targeted therapies, indications, testing methods, and companies developing K-Ras wild-type drugs below.
Search K-Ras wild-type Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting K-Ras wild-type
| Drug | Company | Therapeutic Area |
|---|---|---|
| ERBITUX | IMCLONE | Oncology |
K-Ras wild-type Indications
Head and Neck Cancer Squamous Cell Carcinoma of the Head and Neck Colorectal Cancer BRAF V600E Mutation-Positive Metastatic Colorectal Cancer